Shivan Sivakumar
Overview
Explore the profile of Shivan Sivakumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sivakumar S, Jainarayanan A, Arbe-Barnes E, Sharma P, Ni Leathlobhair M, Amin S, et al.
Nat Commun
. 2025 Feb;
16(1):1397.
PMID: 39915477
Pancreatic ductal adenocarcinoma has a dismal prognosis. A comprehensive analysis of single-cell multi-omic data from matched tumour-infiltrated CD45+ cells and peripheral blood in 12 patients, and two published datasets, reveals...
2.
Go S, Demetriou C, Valenzano G, Hughes S, Lanfredini S, Ferry H, et al.
Elife
. 2024 Dec;
13.
PMID: 39656086
The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate...
3.
Alnagar A, Zakeri N, Koilias K, Faulkes R, Brown R, Cain O, et al.
World J Transplant
. 2024 Sep;
14(3):95849.
PMID: 39295983
Background: Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) has a devastating influence on recipients' survival; however, the risk of recurrence is not routinely stratified. Risk stratification is vital...
4.
Liu D, Puik J, Veno M, Mato Prado M, Rees E, Patel B, et al.
Int J Surg
. 2024 Jul;
110(10):6518-6527.
PMID: 39041944
Background: Biliary obstruction can be due to both malignant and benign pancreaticobiliary disease. Currently, there are no biomarkers that can accurately help make this distinction. MicroRNAs (miRNAs) are stable molecules...
5.
Liu D, Puik J, Patel B, Veno M, Vahabi M, Mato Prado M, et al.
J Exp Clin Cancer Res
. 2024 Jul;
43(1):189.
PMID: 38978141
Background: Distinguishing benign from malignant pancreaticobiliary disease is challenging because of the absence of reliable biomarkers. Circulating extracellular vesicles (EVs) have emerged as functional mediators between cells. Their cargos, including...
6.
Merali N, Chouari T, Sweeney C, Halle-Smith J, Jessel M, Wang B, et al.
Int J Surg
. 2024 Jun;
110(10):6771-6799.
PMID: 38874485
Background: Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), continues to pose a significant clinical and scientific challenge. The most significant finding of recent years is that PDAC tumours harbour their...
7.
Smith H, Arbe-Barnes E, Shah E, Sivakumar S
Front Immunol
. 2024 Jun;
15:1406250.
PMID: 38873607
The five-year survival rates for pancreatic ductal adenocarcinoma (PDAC) have scarcely improved over the last half-century. It is inherently resistant to FDA-approved immunotherapies, which have transformed the outlook for patients...
8.
Merali N, Jessel M, Arbe-Barnes E, Ruby Lee W, Gismondi M, Chouari T, et al.
HPB (Oxford)
. 2024 May;
26(7):873-894.
PMID: 38729813
Background: Pancreatic ductal adenocarcinoma (PDAC) is known to have a heterogeneous desmoplastic tumour microenvironment (TME) with a large number of immunosuppressive cells. Recently, high B-cell infiltration in PDAC has received...
9.
Clift A, Tan P, Patone M, Liao W, Coupland C, Bashford-Rogers R, et al.
Br J Cancer
. 2024 May;
130(12):1969-1978.
PMID: 38702436
Background: The National Institute for Health and Care Excellence (NICE) recommends that people aged 60+ years with newly diagnosed diabetes and weight loss undergo abdominal imaging to assess for pancreatic...
10.
Merali N, Chouari T, Terroire J, Jessel M, Liu D, Smith J, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069211
Pancreatic ductal adenocarcinoma (PDAC) has a very poor survival. The intra-tumoural microbiome can influence pancreatic tumourigenesis and chemoresistance and, therefore, patient survival. The role played by bile microbiota in PDAC...